- Bio Protocol updates tokenomics during V2 phase launch.
- Team tokens delayed, unlocking linearly until May 2026.
- No leadership comments yet on updates.
Bio Protocol initiated its V2 phase on August 3, 2025, introducing updated tokenomics, which include postponing and linearly releasing team and advisor tokens to better manage market impact.
The update could stabilize BIO’s market movement by smoothing sell pressure, as it affects 4.23% of total supply over six months, preventing liquidity shocks.
Bio Protocol has initiated the launch of its V2 phase with a focus on significant tokenomics updates. The company announced a revised vesting schedule for its team and advisor tokens, delaying the one-time unlock initially planned for later this year.
The leadership has not made any public statements regarding the V2 launch and updated tokenomics. Over $29.9 million has been raised across funding rounds (source), with no confirmed impact on other cryptocurrencies like ETH or BTC.
The updated vesting schedule affects the protocol’s native BIO token. However, there are no market comments from key opinion leaders yet. The shift aims to reduce potential sell pressure during upcoming market fluctuations.
Similar vesting strategies in DeFi projects have reduced market volatility. The linear unlocking of 4.23% of the total BIO supply is expected to smooth market impact between November 2025 and May 2026. “The unlock of team and advisor tokens (4.23% of supply) will be postponed and linearly vested over 6 months from November 2025 to May 2026, rather than being unlocked all at once,” stated Bio Protocol Announcement Team.
An unprecedented tranche of 830 million BIO tokens remains unlocked, fully reflecting earlier release figures. Market analysts anticipate positive reception for this strategic move, although official confirmation on V2 features is awaited.
While no regulatory responses have emerged, this move aligns with current DeFi practices. It contributes to a growing trend towards more conservative token release schedules, potentially influencing broader strategy adoption across similar platforms. For more trends and updates, visit TweetScout search results for Bioprotocol.
